Massive Insiderkäufe$$$ Biotech Aktie!!! - 500 Beiträge pro Seite

[scopus]

17-Mar-06 FORBES, CHRISTOPHER
Director 40,000 Direct Purchase at $1.50 per share. $60,000
13-Dec-05 STALDER, RUEDI
Director 10,000 Direct Purchase at $1.40 per share. $14,000
28-Nov-05 FORBES, CHRISTOPHER
Director 30,000 Direct Purchase at $1.49 per share. $44,700
28-Nov-05 BRACA, JOHN N
Director 5,000 Direct Purchase at $1.59 per share. $7,950
22-Nov-05 RECTOR, DAVID
Director 1,000 Direct Purchase at $1.31 per share. $1,310
21-Nov-05 RECTOR, DAVID
Director 3,000 Direct Purchase at $1.27 - $1.34 per share. $3,9152
8-Jun-05 RECTOR, DAVID
Director 2,000 Direct Purchase at $2.24 per share. $4,480
19-May-05 BRACA, JOHN N
Director 3,000 Direct Purchase at $2.19 per share. $6,570
19-May-05 RECTOR, DAVID
Director 3,000 Direct Purchase at $2.22 per share. $6,660
19-May-05 BROOKS, JOEL P.
Chief Financial Officer 2,000 Direct Purchase at $2.26 per share. $4,520
19-May-05 GALTON, BRUCE C.
Chief Executive Officer 3,500 Direct Purchase at $2.25 per share. $7,875
24-Feb-05 RECTOR, DAVID
Director 2,000 Direct Purchase at $2.94 per share. $5,880

[Kostolanys Erbe]

hi,

so etwas nennst du massive insider käufe...???

das sind massive insider VERKÄUFE :-))) und das geht bei google schon seit monaten so... die machen richtig hunderte von millionen an kasse....

http://insider-monitor.com

für deutsche unternehmen
www.insiderdaten.de


Google Rosenberg Jonathan J (VP Prod. Mgmt.) S 888 345.25 306,586 17,860 2006-03-16
REYES GEORGE (Chief Financial Officer) S 742 345.33 256,237 12,688 2006-03-16
REYES GEORGE (Chief Financial Officer) S 1,506 345.08 519,686 12,878 2006-03-16
REYES GEORGE (Chief Financial Officer) S 742 344.60 255,693 13,430 2006-03-15
REYES GEORGE (Chief Financial Officer) S 1,508 344.66 519,749 13,631 2006-03-15
Rosenberg Jonathan J (VP Prod. Mgmt.) S 890 344.77 306,847 18,304 2006-03-15
Page Lawrence (Pres, Products, Asst. Secty) S 116,948 346.09 40,474,855 44,854 2006-03-15
Page Lawrence (Pres, Products, Asst. Secty) S 8,052 342.04 2,754,065 36,802 2006-03-15
REYES GEORGE (Chief Financial Officer) S 742 337.66 250,544 14,172 2006-03-14
REYES GEORGE (Chief Financial Officer) S 1,506 337.12 507,703 14,385 2006-03-14
Rosenberg Jonathan J (VP Prod. Mgmt.) S 888 337.58 299,772 18,749 2006-03-14
Page Lawrence (Pres, Products, Asst. Secty) S 55,688 343.11 19,106,936 106,114 2006-03-13
Page Lawrence (Pres, Products, Asst. Secty) S 69,312 338.35 23,451,659 36,802 2006-03-13
Page Lawrence (Pres, Products, Asst. Secty) S 30,300 348.38 10,555,861 156,502 2006-03-14
Page Lawrence (Pres, Products, Asst. Secty) S 53,660 341.60 18,330,107 102,842 2006-03-14
Page Lawrence (Pres, Products, Asst. Secty) S 57,040 336.68 19,204,050 45,802 2006-03-14
Page Lawrence (Pres, Products, Asst. Secty) S 9,000 334.39 3,009,510 36,802 2006-03-14
Brin Sergey (President, Tech, Asst. Secty) S 50,417 355.65 17,930,910 128,645 2006-03-08
Brin Sergey (President, Tech, Asst. Secty) S 79,583 353.14 28,104,046 49,062 2006-03-08
Brin Sergey (President, Tech, Asst. Secty) S 8,000 361.75 2,894,000 94,062 2006-03-06
Brin Sergey (President, Tech, Asst. Secty) S 112,524 363.85 40,941,415 67,062 2006-03-07
Brin Sergey (President, Tech, Asst. Secty) S 18,000 359.50 6,471,000 49,062 2006-03-07
Rosenberg Jonathan J (VP Prod. Mgmt.) S 5,916 362.78 2,146,200 122,810 2006-03-07
REYES GEORGE (Chief Financial Officer) S 4,566 362.84 1,656,741 83,160 2006-03-07
Rosenberg Jonathan J (VP Prod. Mgmt.) S 5,915 379.36 2,243,941 112,559 2006-03-06
REYES GEORGE (Chief Financial Officer) S 4,565 379.11 1,730,617 71,060 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 7,175 382.61 2,745,206 922,142 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 13,042 382.01 4,982,207 909,100 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 12,318 381.63 4,700,869 896,782 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 13,300 381.27 5,070,886 883,482 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 15,605 380.41 5,936,320 867,877 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 14,129 379.39 5,360,391 853,748 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 17,514 378.66 6,631,851 836,234 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 13,223 374.74 4,955,172 823,011 2006-03-06
Brin Sergey (President, Tech, Asst. Secty) S 120,088 374.24 44,941,815 60,450 2006-03-06
Brin Sergey (President, Tech, Asst. Secty) S 11,388 368.10 4,191,979 49,062 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 15,860 371.05 5,884,909 795,191 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 11,960 371.93 4,448,278 811,051 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 29,801 370.01 11,026,678 765,390 2006-03-06
Kordestani Omid (SVP, World Wide Sales/Oper.) S 11,282 368.05 4,152,370 754,108 2006-03-06
Rosenberg Jonathan J (VP Prod. Mgmt.) S 5,915 382.72 2,263,800 118,474 2006-03-03
REYES GEORGE (Chief Financial Officer) S 4,565 382.91 1,747,986 75,625 2006-03-03
Brown Shona L (VP Business Oper.) S 2,541 383.88 975,432 0 2006-03-03
REYES GEORGE (Chief Financial Officer) S 4,565 367.08 1,675,722 80,190 2006-03-02
Rosenberg Jonathan J (VP Prod. Mgmt.) S 5,915 367.56 2,174,107 124,389 2006-03-02
REYES GEORGE (Chief Financial Officer) S 4,565 365.19 1,667,092 84,755 2006-03-01
Rosenberg Jonathan J (VP Prod. Mgmt.) S 5,915 365.07 2,159,362 130,304 2006-03-01
Drummond David C (VP, Gen. Counsel, Secty) S 4,456 365.13 1,627,022 185,144 2006-03-01
Drummond David C (VP, Gen. Counsel, Secty) S 1,938 363.66 704,768 183,256 2006-03-01
Drummond David C (VP, Gen. Counsel, Secty) S 20,950 365.26 7,652,235 12,806 2006-03-01
Drummond David C (VP, Gen. Counsel, Secty) S 12,806 364.00 4,661,429 0 2006-03-01
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 4,641 395.33 1,834,733 62,935 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 5,063 393.55 1,992,540 57,872 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,547 372.76 949,425 55,325 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,136 368.72 787,585 53,189 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,579 365.93 943,723 50,610 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,931 364.72 1,069,008 47,679 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,818 363.58 1,024,556 44,861 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 3,563 362.46 1,291,434 41,298 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 3,567 361.30 1,288,759 37,731 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 3,229 359.84 1,161,939 34,502 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,613 358.11 935,747 31,889 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,543 354.57 901,659 29,346 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,406 352.30 847,636 26,940 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,579 349.54 551,916 25,361 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 150 395.33 59,299 9,539 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 217 393.55 85,400 9,322 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 111 372.76 41,376 9,211 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 93 368.72 34,290 9,118 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 111 365.93 40,617 9,007 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 127 364.72 46,320 8,880 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 122 363.58 44,356 8,758 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 154 362.46 55,818 8,604 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 155 361.30 56,001 8,449 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 141 359.84 50,738 8,308 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 112 358.11 40,108 8,196 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 111 354.57 39,356 8,085 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 105 352.30 36,991 7,980 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 69 349.54 24,117 7,911 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,418 395.33 560,580 11,082 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,501 393.55 590,717 9,581 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 747 372.76 278,453 8,834 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 623 368.72 229,712 8,211 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 758 365.93 277,371 7,453 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 866 364.72 315,851 6,587 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 831 363.58 302,131 5,756 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,052 362.46 381,304 4,704 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,055 361.30 381,172 3,649 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 954 359.84 343,292 2,695 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 768 358.11 275,030 1,927 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 750 354.57 265,924 1,177 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 709 352.30 249,781 468 2006-02-28
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 468 349.54 163,582 0 2006-02-28
HENNESSY JOHN L (Director) S 140 387.32 54,224 0 2006-02-27
HENNESSY JOHN L (Director) S 140 377.18 52,804 0 2006-02-24
Eustace Robert Alan (Vice President of Engineering) S 1,400 367.08 513,916 47,525 2006-02-23
HENNESSY JOHN L (Director) S 140 376.02 52,642 0 2006-02-23
DOERR L JOHN (Director) S 53,800 375.45 20,199,210 0 2006-02-23
Eustace Robert Alan (Vice President of Engineering) S 5,395 376.16 2,029,383 48,925 2006-02-23
HENNESSY JOHN L (Director) S 140 366.27 51,277 0 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 4,932 367.53 1,812,676 67,644 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 4,808 367.08 1,764,942 62,836 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 4,534 366.60 1,662,151 58,302 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 9,892 366.09 3,621,394 48,410 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 7,605 365.76 2,781,621 40,805 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 5,246 365.40 1,916,912 35,559 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 5,198 364.92 1,896,854 30,361 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 188 367.53 69,096 9,502 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 205 367.08 75,252 9,297 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 196 366.60 71,853 9,101 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 420 366.09 153,759 8,681 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 321 365.76 117,409 8,360 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 224 365.40 81,850 8,136 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 225 364.92 82,107 7,911 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,468 367.53 539,539 11,032 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,424 367.08 522,728 9,608 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,340 366.60 491,240 8,268 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,924 366.09 1,070,456 5,344 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 2,255 365.76 824,793 3,089 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,551 365.40 566,742 1,538 2006-02-22
SCHMIDT ERIC E (CEO, Chairman of Exec. Comm.) S 1,538 364.92 561,246 0 2006-02-22
REYES GEORGE (Chief Financial Officer) S 742 368.15 273,169 14,914 2006-02-21
REYES GEORGE (Chief Financial Officer) S 1,506 368.02 554,237 15,138 2006-02-21
Rosenberg Jonathan J (VP Prod. Mgmt.) S 888 368.02 326,799 19,193 2006-02-21
HENNESSY JOHN L (Director) S 140 368.21 51,549 0 2006-02-21
REYES GEORGE (Chief Financial Officer) S 742 368.76 273,622 15,656 2006-02-17
REYES GEORGE (Chief Financial Officer) S 1,508 368.84 556,214 15,891 2006-02-17
Rosenberg Jonathan J (VP Prod. Mgmt.) S 890 368.82 328,250 19,637 2006-02-17
REYES GEORGE (Chief Financial Officer) S 742 353.13 262,023 16,398 2006-02-16
REYES GEORGE (Chief Financial Officer) S 1,506 352.78 531,290 16,645 2006-02-16
Rosenberg Jonathan J (VP Prod. Mgmt.) S 888 352.32 312,861 20,082 2006-02-16
Shriram Kavitark Ram (Director) S 3,647 348.40 1,270,608 309,034 2006-02-16
Shriram Kavitark Ram (Director) S 3,647 348.40 1,270,608 309,034 2006-02-16
Kordestani Omid (SVP, World Wide Sales/Oper.) S 200 358.23 71,646 97,311 2006-01-17
Kordestani Omid (SVP, World Wide Sales/Oper.) S 2,817 358.12 1,008,816 96,846 2006-02-16
Kordestani Omid (SVP, World Wide Sales/Oper.) S 200 351.30 70,259 94,596 2006-01-17
Kordestani Omid (SVP, World Wide Sales/Oper.) S 2,579 350.76 904,611 94,067 2006-02-16
Kordestani Omid (SVP, World Wide Sales/Oper.) S 200 345.67 69,134 91,757 2006-01-17
Kordestani Omid (SVP, World Wide Sales/Oper.) S 2,610 345.68 902,230 91,257 2006-02-16
Kordestani Omid (SVP, World Wide Sales/Oper.) S 200 357.92 71,585 97,328 2006-01-17
Kordestani Omid (SVP, World Wide Sales/Oper.) S 2,816 358.06 1,008,304 96,847 2006-02-16
Kordestani Omid (SVP, World Wide Sales/Oper.) S 200 350.66 70,133 94,447 2006-01-17
Kordestani Omid (SVP, World Wide Sales/Oper.) S 2,800 350.39 981,102 93,847 2006-02-16
Kordestani Omid (SVP, World Wide Sales/Oper.) S 200 345.80 69,161 91,757 2006-01-17
Kordestani Omid (SVP, World Wide Sales/Oper.) S 2,390 345.69 826,208 91,257 2006-02-16
Shriram Kavitark Ram (Director) S 14,104 468.01 6,600,745 294,930 2006-02-16
Shriram Kavitark Ram (Director) S 282,256 347.39 98,053,589 49,993 2006-02-16
Shriram Kavitark Ram (Director) S 623 348.37 217,034 49,370 2006-02-16
Shriram Kavitark Ram (Director) S 2,343 347.98 815,326 47,027 2006-02-16
Shriram Kavitark Ram (Director) S 47,027 347.32 16,333,192 0 2006-02-16
Page Lawrence (Pres, Products, Asst. Secty) S 139,000 343.23 47,709,017 36,802 2006-02-15
Rosenberg Jonathan J (VP Prod. Mgmt.) S 890 342.60 304,911 20,526 2006-02-15
REYES GEORGE (Chief Financial Officer) S 742 342.52 254,152 17,140 2006-02-15
REYES GEORGE (Chief Financial Officer) S 1,508 342.57 516,589 17,398 2006-02-15
REYES GEORGE (Chief Financial Officer) S 742 345.49 256,352 17,882 2006-02-14
REYES GEORGE (Chief Financial Officer) S 1,506 345.51 520,341 18,152 2006-02-14
Rosenberg Jonathan J (VP Prod. Mgmt.) S 888 345.61 306,900 20,971 2006-02-14
Drummond David C (VP, Gen. Counsel, Secty) S 10,100 346.00 3,494,600 189,600 2006-02-14
Page Lawrence (Pres, Products, Asst. Secty) S 100 351.06 35,106 160,827 2006-02-13
Page Lawrence (Pres, Products, Asst. Secty) S 69,129 348.74 24,107,899 94,573 2006-02-14
Page Lawrence (Pres, Products, Asst. Secty) S 7,862 345.75 2,718,286 82,079 2006-02-13
Page Lawrence (Pres, Products, Asst. Secty) S 49,909 344.46 17,191,440 36,802 2006-02-14
Page Lawrence (Pres, Products, Asst. Secty) S 134,000 346.14 46,382,137 36,802 2006-02-13

[felici]

mhh

auch im ethanol bereich!!!


http://www.senesco.com/broin.htm

In October, 2004, we entered into a license agreement with the Broin Companies to license our proprietary gene technology to Broin to improve aspects of Broin’s ethanol production capabilities. We will receive an annual payment for each Broin facility that incorporates our technology.

[scopus]

News!!


Senesco`s Technology Increases Pancreatic Islet Cell Survivability in Animal Study
Wednesday March 22, 7:00 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 22, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX: SNT - News) announced today that a preclinical animal study has shown that the Company`s proprietary gene technology increases the survivability of islets isolated for transplantation. Islets are the insulin producing cells located in the mammalian pancreas.
ADVERTISEMENT





Diabetes is a growing health problem in the developed world, with daily insulin injections being a common primary treatment. The transplantation of the insulin-producing islets from donors has progressed during the past five years. Most promising is the fact that patients whose condition is difficult to control with insulin have a rapid return to normal blood glucose upon islet transplantation. Unfortunately, islet transplantation typically requires cells from two donors and a large number of islets die during harvest due to isolation methods requiring digestive enzymes.

Dr. Eli C. Lewis, working in the laboratory of Dr. Charles Dinarello at the University of Colorado, investigated the role of the Company`s eIF-5A1 (otherwise referred to as "Factor 5A") gene technology during the process of islet isolation for transplantation using a well-established mouse model. The team used a small interfering RNA ("siRNA") that downregulates expression of eIF-5A1, which the Company has shown reduces cell death in a variety of models. The researchers observed a significant increase in the survival of insulin-producing islets when mice received an infusion of the siRNA to eIF-51A compared to a control siRNA. In a concurrent study, the investigators showed that death of islets resulting from exposure to IL-1beta and interferon-gamma was also significantly reduced, meaning more viable islets remained.

Dr. Dinarello, a member of the Company`s Scientific Advisory Board, said of the results, "The implications of these results for human islets transplantation are important since this siRNA can yield more viable (live) islets while increasing the number of transplantations that can be performed. Presently, one of the major drawbacks of islet transplantation is the low number of live islets that can be obtained for transplantation. The promise of this novel approach will be welcome to the field."

About Senesco Technologies, Inc.

Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners` products. Senesco is headquartered in New Brunswick, New Jersey.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company`s gene technology; the approval of the Company`s patent applications; the successful implementation of the Company`s research and development programs and joint ventures; the success of the Company`s license agreements; the acceptance by the market of the Company`s products; success of the Company`s preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company`s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company`s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.



Contact:
Senesco Technologies, Inc.
Bruce Galton, Chief Executive Officer, 732-296-8400
[e-mail]
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, 212-838-3777
Kim Sutton Golodetz
[e-mail]
or
Anne Marie Fields
[e-mail]

--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.

[scopus]

GOOOOOOOOOOOOOOO

[scopus]

ethanol phantasie

http://www.senesco.com/broin.htm

[scopus]

Hammer News

Senesco's Technology Inhibits Tumor Development and Increases Longevity in Mouse Cancer Model
Thursday April 27, 6:00 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--April 27, 2006--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today the results of a study conducted in Dr. John Thompson's laboratory at the University of Waterloo in Ontario, Canada, in which mice injected with tumor-forming B16F0 melanoma cancer cells were treated with Senesco's proprietary gene, eIF-5A ("Factor 5A"). Tumors of adequate size formed in approximately nine days at which time treatment was initiated. Two control groups of nine mice each received placebo treatments and a test group of ten mice received Factor 5A, intratumorally, every other day. The median survival of the control mice was 7 days post-treatment, whereas, the mice that received Factor 5A treatment had a median survival of 25 days post-treatment (P less than 0.001). The enhanced survival time of the Factor 5A-treated mice equates to 3.5 fold or a 250% increase compared to the control mice. Two of the Factor 5A-treated mice are still alive, with one mouse in apparent complete remission. None of the control mice survived.
ADVERTISEMENT


In addition to this enhancement of survival, the tumors in the treated mice remained smaller and grew more slowly than those in the control mice.

Dr. Thompson, the Company's Executive Vice President of Research and Development, commented, "These data build upon our previous preclinical cancer studies and provide more evidence for Factor 5A as an anti-cancer agent. It is very heartening to see reduced tumor growth rates in the treated mice."

Future studies may focus on optimizing delivery of Factor 5A to tumors to determine if there would be an enhancement of treatment.

About Senesco Technologies, Inc.

Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; and competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.



Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
[e-mail]
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
[e-mail]
[e-mail]

--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.

[scopus]

senesco ist zu billig!

könnte bis 10$ laufen!

eine ethanol news....dann gehts ab

[scopus]

up

[scopus]

[scopus]

keiner dabei?

[scopus]

[scopus]

Hammer News

mit Bayer


Bayer CropScience Licenses Rights to Senesco Technologies' Gene Technology
Thursday November 9, 7:00 am ET


NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT - News) announced today that Bayer CropScience has exclusively licensed the rights to Senesco's proprietary gene technology for use in Brassica oilseeds. The agreement anticipates that the licensed technology will enable Bayer CropScience to significantly enhance Canola yields in its InVigor® and future hybrid's business on a global basis. In return, Senesco will receive success-bound development milestone and commercialization payments. Specific financial terms of the transaction were not disclosed.


"Senesco is proud to have Bayer CropScience as a partner for this important crop. We look forward to working with Bayer CropScience due to their marketing strength and commitment to science," said Bruce Galton, President of Senesco.

Dr. Michiel van Lookeren Campagne, Head of Research at BioScience, a business operations unit of Bayer CropScience, welcomes the new business relationship with Senesco: "Bayer CropScience has grown to be a leading company in the canola seed market with InVigor®, our high quality, high yield Canola hybrid varieties. Senesco has shown that the seed yield of Canola can be significantly increased by modulating the expression of its proprietary genes. We anticipate that the innovative Senesco technology will contribute to further strengthen our leadership position in the global hybrid Canola markets."

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey.

About Bayer CropScience

Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 6 billion, is one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries.

Your contact:
Bayer CropScience
Annette Josten, phone: [phone]
E-Mail: [e-mail]
www.bayercropscience.com

Senesco Technologies, Inc.
Bruce C. Galton, phone: [phone]
President & CEO
Email: [e-mail]
www.senesco.com

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer CropScience AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future consolidated results, financial situation, development or performance of the Bayer CropScience AG or our parent company, Bayer AG, and the estimates given here. These factors include those discussed in Bayer AG's public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Bayer AG's Form 20-F). Neither Bayer AG nor Bayer CropScience AG assumes any liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

For Senesco: Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.



Contact:
Company Contact:
Senesco Technologies, Inc.
Bruce Galton, 732-296-8400
Chief Executive Officer
[e-mail]
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz/Anne Marie Fields, 212-838-3777
[e-mail]
[e-mail]

--------------------------------------------------------------------------------
Source: Senesco Technologies, Inc.